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Chapter 1: Introduction
1.1 Overview of respiratory syncytial virus
Human respiratory syncytial virus (hRSV) is a common respiratory pathogen that causes
significant morbidity and mortality in infants as well as the elderly and the immunocompromised
around the world. Annually 33 million pediatric cases of acute lower respiratory tract infection
(LRTI) and over 60,000 deaths can be attributed to hRSV1–5. The virus is known to suppress the
host immune response, a phenomenon that has been associated with the high rate of reinfection6–
8

. hRSV is also associated with a higher incidence of asthma1,2,9 and other respiratory inflammatory

diseases. Current treatments do not fully address the burden of disease10,11. No vaccine is currently
available12–15, although several are in Phase I-III clinical trials16–18. This situation calls for
continuing research into the basic biology of hRSV to develop new preventive and therapeutic
options for treatment.
hRSV is a single-stranded negative-sense RNA virus in the genus Pneumoviridae 19. The ten
genes in its genome code for 11 proteins20. hRSV performs mRNA transcription using the L, N,
P, and M2-1/2 proteins21. The L (large polymerase) protein, an RNA-dependent RNA polymerase
(RdRP), transcribes RNAs from the genome. In hRSV, there are gene start (GS) and gene end
(GE) signals flanking each open reading frame (ORF), which are used in a stop-start mechanism
wherein each gene must be fully transcribed (mediated by GE) before the next GS signal is read22.
The M2-1 protein regulates processivity, wherein the L protein either obeys or bypasses GS and
GE factors during genome replication. Replication produces a positive-sense antigenome as a
replication intermediate. mRNA transcription begins from the 3’ end of the genome, and due to
the stop-start mechanism, the genes at the 3’ end are produced most abundantly. As infection
continues, the virus switches from RNA transcription to genome replication in preparation for
1

release of new virions23. M2-2, a processivity factor, accumulates throughout infection. As M2-2
allows the RdRP to continue transcribing the full genome rather than discrete ORFs, this leads to
genome replication instead of RNA transcription24.
RSV encodes two unique proteins that perform multiple immune antagonist functions,
nonstructural protein 1 (NS1) and nonstructural protein 2 (NS2). Following these genes in the
genome are Nucleoprotein, Phosphoprotein, Matrix, Small Hydrophobic Protein, Glycoprotein,
Fusion, M2 (with two ORFs 1 and 2) and L, the large RdRp23.The two transcript variants of M2
control the switch between transcription processivity and RNA replication. N and P are needed for
encapsidation, those two plus L for RNA replication, and those three plus M2-1 for transcription
processivity. M2-2 downregulates transcription and upregulates RNA replication or in other
words, replication of the full negative-sense genome via a sense intermediate.

1.2 hRSV NS1 encodes a unique multifunctional interferon antagonist protein
NS1 and NS2, the first two genes transcribed starting at the 3’ end of the genome, are produced
abundantly early during infection. In cells infected with recombinant RSV minigenomes with NS1
deleted, NS2 is more abundant than in WT RSV-infected cells25; NS1 also inhibits genome
replication and mRNA transcription of hRSV26. NS1 immunoprecipitates with Matrix protein27.
The 142 amino acid long sequence of NS1 has an approximate molecular weight of 17 kDa.
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Spann, Tran, and Collins showed localization of NS1 and NS2 in both the cytoplasm and
nucleus of hRSV-infected cells via Western blot using a polyclonal serum that detects both NS
proteins28. A similar antiserum has been used as early as 1998 to detect both NS proteins26. While
designed against the C-terminal 10 amino acids of NS2, the two proteins share the terminal DLNP
peptide. This is thought to be the basis for the recognition of both
proteins by the antiserum used by Atreya et al26. In 2009,
Swedan et al29 performed immunofluorescence on A549s
transiently transfected with individual FLAG-tagged NS1 or
NS2 protein. They found cytoplasmic localization as well as
overlap of both NS1 and NS2 localization with DAPI-stained

Figure 1. Image from
Chatterjee et al., Nature
Microbiology, 2017

nuclei.
The crystal structure of hRSV NS1 was recently solved by our collaborators in the Leung
group30 (Figure 1.1). The NS1 crystal structure reveals significant structural homology to the NTD
of hRSV Matrix30 while the NS1 structure contains additional features not present in the Matrix
structure. Specifically, it has a β5 sheet in the NTD, a reversal in direction of another sheet, and a
C-terminal α3 helix that is not present in Matrix. This gene has no homologs in any other viruses
outside of the Orthopneumoviridae clade, encompassing hRSV and its animal orthologs, which
include bovine RSV (bRSV) and pneumonia virus of mice (PVM)31. The closest relatives of RSV,
the Metapneumoviridae, do not encode orthologs to NS1.
Separately from and together with the other non-structural protein NS2, NS1 acts to
antagonize immune response to RSV infection. Known activities of NS1 occur in the cytoplasm.
Spann and colleagues found that NS1/NS2 deletion RSV has attenuated replication in type I IFN
competent cells32. They also found that IFNα/β/λ were more highly expressed in A549s and
3

macrophages in response to infection with single or double NS deletion viruses than to wild type
virus.

They

later

showed

that

NS1

inhibits

IRF3

nuclear

translocation28.

Using

immunofluorescence to image apoptosis with TUNEL stain, Bitko and colleagues showed that
each NS protein has an anti-apoptotic role33. They used siRNA against NS1 or NS2 in hRSVinfected cells and demonstrated an increase in apoptosis in hRSV infected cells33. Elliott and
colleagues further demonstrated that NS1 and NS2 cooperate in the degradation of STAT234.
Furthermore, they showed that NS1 has homology to E3 ligase components and can bind CUL2
domains. They found NS1 degrades STAT2 by promoting K48 ubiquitination. Here they used
tagged NS1/NS2 & ubiquitination complex components, and siRNA against NS1/2. Finally, they
used bioinformatics to identify NS1 regions homologous to ubiquitin complex components. Taken
together, these data suggest that NS1 antagonizes interferon responses in RSV infected cells.

1.3 Experimental evidence indicates a likely nuclear role for hRSV NS1
This section of the background will highlight major points from a previous publication by
our collaborators, the Leung group, with relevance to my dissertation research. As previously
mentioned, the NS1 protein consists of a core connected to an alpha helix (α3) by a flexible linker
domain (Figure 1.1). The core contains two alpha helices and two beta sheets. The primary form
of NS1 is thought to be the monomer. Alanine mutants of residues throughout the protein were
generated based on the crystal structure. Within the α3 helix, mutants were generated at Y125 and
L132/L133. A truncation mutant of NS1 was generated as well, NS1 1-118; this mutant excludes
the alpha-three helix encompassing residues 119-142. hRSV carrying either wild-type or mutant
NS1 was used to infect A549s, after which RNA was harvested at 24,48, and 96 hours post
infection (h.p.i). Alanine mutated residues in the core did not significantly affect the transcriptional
4

response to RSV. However, mutations in the α3 helix, including NS1 Y125A, resulted in
significantly different transcriptional profiles compared to WT NS1 infection (Figure 3.6). While
there are some transcriptomic differences between mock, 24 and 48 h.p.i for α3 helix mutant NS1
RSV infections, they are less profound than WT or core residue mutant NS1 infections30.
Moreover, at 96 h.p.i., transcription levels in α3 helix mutant NS1 infections are essentially
equivalent to mock infection (Figure 3.6). This suggests that the transcriptional response to RSV
was altered by mutation of the α3 helix residues but not of the core residues. I interpret this
observation as indicating that wild-type NS1 enables hRSV to persist in the cell, inducing an
antiviral response longer than α3 helix mutant NS1.
Much of the transcriptional response to RSV infection involves interferon signaling. The
IFN-β promoter is a primary target of the type I interferon induction pathway. The Leung group
tested the impact of NS1 on IRF3-driven transcription using an IFN-β promoter reporter 30. That
NS1 mutants have a significant effect on gene transcription throughout infection suggested that
NS1 might be active in the nucleus. However, NS1 is known to restrict IRF3 nuclear entry28,35.
The Leung group bypassed this issue by using a mutant of IRF3 that was constitutively active and
nuclear-localized: IRF3-5D36,37. Five residues were mutated to aspartic acid resulting in a
constitutively active phosphomimetic. Activated IRF3, whether phosphorylated WT or IRF3-5D,
dimerizes, translocates to the nucleus, and binds regulatory elements.
A plasmid constitutively expressing IRF3-5D with or without a plasmid constitutively
expressing NS1 was transfected into Sendai virus infected A549 cells to further determine whether
gene expression under control of the IFN-β promoter was altered in the presence of NS130. The
Leung group then carried out luciferase reporter assay under the control of the IFN-β promoter.
The IFN-β promoter, the target of the luciferase reporter assay, is one of the best characterized
5

Figure 1.2. Schematic of the type I interferon induction and response pathways. Innate immune
response depends on sensing pathogen associated molecular patterns, or non-self molecules
associated with infection. Several families of pattern recognition receptors (PRRs) identify
different features of PAMPs. For the purposes of this talk, I am focusing on two PRRs that
detect RNA virus patterns: RIG-I, a cytoplasmic PRR; and TLR-3, an endosomal PRR, both
of which recognize double stranded RNA. Once activated upon detection of double stranded
RNA, RIG-I initiates signaling that leads to the phosphorylation, dimerization, and nuclear
translocation of IRF3. Once localized in the nucleus, IRF3 binds sequence specific motifs at
the regulatory elements of innate immune response genes. Downstream of TLR3 activation,
NF-kB dimers are released from inhibition by inhibitor of kappa B kinases A and B (IKKα/β),
allowing it to translocate to the nucleus and bind its own sequence specific regulatory elements.
Among the genes targeted by the IRF3 and NF-kB transcription factors is interferon-β, a
type I interferon that can act in an autocrine or paracrine manner to induce the cell in which it
is detected to adopt an antiviral state. Type I IFN receptors on the cell membrane bind IFN-β,
leading to the formation of the ISGF3 complex from IRF9 and phosphorylated STAT1 and
STAT2. ISGF3 then translocates to the nucleus, where it binds interferon stimulated regulatory
element motifs – as does IRF3 – at a wide selection of interferon stimulated genes, which when
expressed put the cell into the antiviral state.
promoters for which expression may be induced by IRF3. Reporter expression was strongly
6

upregulated when IRF3-5D was added but partially reduced when NS1 is added. This suggests
that a cytoplasmic role of NS1 is not sufficient to explain its ability to reduce gene expression and
supports a nuclear role for NS1 to modulate reporter gene expression downstream of the IRF3
activation recapitulated by IRF3-5D. Taken together, these findings suggest a role for NS1 to play
in the transcriptional regulation of innate immune response and interferon signaling genes in the
nucleus.

1.4 NS1 immunoprecipitates with several components of the Mediator transcriptional regulatory
complex
Affinity precipitation followed by mass spectrometry (AP-MS) experiments with NS1 as
bait pulled down many subunits of the Mediator complex38,39. As discussed earlier, RSV replicates
its genome and transcribes mRNAs in the cytoplasm. Mediator is a chromatin-associated nuclearlocalized transcriptional regulatory complex40, found at active promoters and enhancers, bridging
the two into closer proximity and enhancing the activity of RNA Pol II40. Mediator also has other
activities41,42. It consists of three evolutionarily conserved modules: head, middle, and tail43 and
for which the majority of constituent polypeptides are conserved between yeast and human
encompassing all three modules. The Head module interacts with RNA Pol II and the pre-initiation
complex (PIC) at the core promoter elements of transcriptionally active genes. Several subunits of
Mediator interact with the PIC component TFIIH44. The MED14 subunit of Mediator connects the
head, middle, and tail44. The most evolutionarily diverged polypeptides of Mediator are those in
the Tail module. This region of Mediator interacts with tissue specific transcription factors found
at the enhancer regions of actively transcribed genes41–46.

7

1.5 NS2 is the other unique interferon antagonist of hRSV
Aside from NS1, hRSV encodes a second unique interferon antagonist23. Like NS1, NS2
has a unique primary sequence excepting the C-terminal DLNP peptide. With the discovery of the
crystal structure of NS247, the Leung group demonstrated that NS2 binds an inactive form of the
RIG-I and MDA-5 signaling molecules, with the N-terminal residues of NS2 directly involved in
the binding interaction. This agrees with previous work that showed that NS2 interacts with the Nterminal caspase activation and recruitment domain (CARD) of RIG-I, disrupting its association
with MAVS48. This interaction is a key step in the RIG-I signaling pathway, and the disruption
prevents accumulation of IRF3 in the nucleus.
Deletion of NS2 alone or with NS1 attenuates infectivity of hRSV in interferon competent
cells28,32,47, indicating that NS2 plays an interferon-dependent role in infectivity. Beyond the
interaction with RIG-I and MDA-5 described above, several groups have described additional
interferon antagonist roles for NS2. Lo and colleagues demonstrated that NS2 leads to a decrease
in STAT2 and responsiveness to the type I IFN signaling pathway49. Spann et al. showed that NS2
partitions predominantly to the cytoplasm and also to the nucleus of infected cells28. Elliott and
colleagues showed that NS1 and NS2 contribute to the proteasomal degradation of STAT234. Thus,
NS2 is a second multifunctional interferon antagonist protein encoded by hRSV.

1.6 hRSV Matrix is a structural protein with structural homology to NS1
hRSV NS1 shares significant structural homology with the hRSV Matrix protein30. Matrix
is one of four proteins, along with F, N, and P, required for hRSV virus-like particle formation and
budding50. As a structural protein, Matrix forms a shell around the nucleocapsid and interacts with
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the viral envelope23. It has a short hydrophobic region, but not a full-fledged transmembrane
domain, via which it transiently interacts with the host cell membrane51.
Early during the infectious life cycle of hRSV, Matrix localizes to the nucleus using its bipartite
nuclear localization (bpNLS) sequence in its interaction with IMPβ1-family importin22,50,52,53.
Inhibition of nuclear export via IMPβ1-family inhibition using verdinexor restricts the budding of
hRSV54. Importin family nuclear export receptor CRM155, an IMPβ1- related exportin, is
responsible for nuclear egress of Matrix56. This suggests that hRSV Matrix must enter and then
exit the nucleus for the virus to bud.
Furthermore, hRSV Matrix is implicated in transcriptional repression while it is nuclear
localized52. However, I raise an issue with this conclusion. The experiments in the relevant paper
observed host transcriptional repression in the presence of nuclear extract from hRSV-infected
cells but did not confirm using isolated Matrix. Their conclusion assumed that Matrix was the only
hRSV protein found to be in the nucleus and therefore was the causative agent52. However, our
results demonstrating nuclear localization of NS139 suggest a potential alternative explanation for
this phenomenon.
hRSV Matrix has sequence and structural homology to many other NNSV Matrix proteins
and shares many functions with them57,58. Paramyxovirus Matrix proteins share a nuclear export
signal (NES) and a bipartite nuclear localization signal (bpNLS) with a required ubiquitinatable
lysine57,59,60. Matrix of Newcastle disease virus (NDV) can also localize to the nucleus via a
different mechanism60,61; henipavirus (Nipah, Hendra) Matrix proteins do as well59,62; measles
virus Matrix has been shown to inhibit host cell transcription63.

9

1.7 Host epithelial cells activate innate immune signaling pathways upon recognition of infection
hRSV infects respiratory epithelium throughout the respiratory tract1,23,64. In healthy adults,
RSV infects tissue of the nasopharynx, or upper respiratory tract leading to a mild infection with
cold-like symptoms. However, in high-risk groups the immune response is lacking, which allows
hRSV to infect tissues throughout the respiratory tract up to and including the lung tissue.
The respiratory tract is lined with epithelial cells65. This tissue constantly interacts with the
environment and functions as an interface between the lungs and inhaled environmental air. It is
therefore one of the first lines of defense against airborne pathogens65,66. Respiratory tract
epithelial cells are part of the innate immune system. Surface molecules and other receptors
throughout the cell67,68 known as pattern recognition receptors (PRRs) allow type II lung epithelial
cells (ciliated alveolar epithelial cells) and other innate immune cells to recognize infectious
material. The PRRs consist of three families of receptors (RIG-I like receptors [RLRs]; Toll-like
receptors [TLRs]; and Nod-like receptors [NLRs]) that recognize pathogen-associated molecular
patterns (PAMPs), usually molecules in forms that do not occur in mammalian cells.
PRR mediated signaling pathways generally lead to the induction of interferon signaling,
which allows the cell and those around it to adopt an “antiviral state” that is less sensitive to
infection69,70. Interferon signaling, which potentiates this state, leads to transcriptional induction
of a suite of interferon stimulated genes64,71–73. This state precipitates the secretion of inflammatory
mediators that recruit the other types of cells within the immune system to respond to infection
and induces paracrine signaling that allows nearby cells to adopt an antiviral state64,71,74. The RIGlike receptors (RLRs), RIG-I, MDA-5 are the major recognizers of hRSV infection47,48,75,76.
Activation of RIG-I or MDA-5 leads to a signaling cascade that results in interferon (IFN)
upregulation and the production of IFN-stimulated genes (ISGs, also termed IFN-regulated genes,
10

IRGs). Within the toll-like receptors, TLR3 is endosomal and is known to sense hRSV RNA as
well22,68,77.
The immune response can be divided into the innate and adaptive phases8,67,78–80. During the
innate immune response, host cells rapidly detect and respond to molecules associated with
infection64. In contrast, the adaptive immune response depends on antigen recognition and happens
slowly after the first encounter with a pathogen; dedicated cell types including B cells, T cells, and
dendritic cells carry out adaptive immune functions. The innate immune response is important
because it happens quickly, within hours to days of infection. The rapid replication of microbial
pathogens requires a fast-acting response.
PAMPs can be grouped into several types of pathogenic molecules common to a class of
infectious pathogens and that have physical attributes not seen in mammalian cells. Examples
include peptidoglycan, lipopolysaccharide, and non 5’ capped single stranded RNA67,78. Common
PAMPs include double-stranded RNA lacking canonical post-translational modifications such as
a 5’ cap. DAMPs, or damage associated molecular patterns, are also recognized by PRRs. These
are host molecules usually detectable by PRRs when localized inappropriately81. RIG-I recognizes
short, unmodified dsRNA, while MDA-5 recognizes long dsRNAs67,78. Eukaryotic mRNA is
usually modified with a 5’ cap and 3’ poly-adenylation, but the mRNA of viral pathogens is
not76,82.
To persist long enough to generate virions that will go on to enter new nearby cells, an
infectious pathogen must combat the innate immune response of the infected host cell64. Successful
pathogens have evolved a range of biochemical processes that allow them to evade these responses.
For example in the case of the uncapped mRNA, some viruses have the ability to “snatch” the
5’ppp cap from mammalian RNAs83 so they are not recognized as foreign by RIG-I. These mRNAs
11

can then be translated into functional proteins, undisturbed by the innate immune machinery within
the infected cell.
Viruses also commonly encode proteins with immune antagonist functions. Many nonstructural (NS) proteins, so named because they do not form part of the infectious virion, serve
this function across a range of viruses. Influenza virus NS184, unrelated to hRSV NS1, is an
antagonist, as is Ebolavirus VP3585. From the ssnsRNA viruses, these proteins tend to function in
the cytoplasm or at the mitochondrial membrane blocking upstream steps of type I IFN induction
via binding PRRs or their adaptors and blocking signal transduction.
The genome of RSV is a negative sense RNA genome that can immediately produce sense
mRNA transcripts21–23. However, the RNA transcripts of hRSV are the ligand for RIG-I, activating
the innate immune response to viral infection. RIG-I ligand binding activates a signaling pathway
that leads to the transcription of IFN86 and a subset of other genes activated directly downstream
of RIG-I and TLR3 signaling (Figure 1.2). Upon activation of RIG-I, nuclear translocation of IFN
regulatory factor family transcription factors then drives transcription. The IRF3 transcription
factor is constitutively expressed but inactive pending post-translational modification. RIG-I
signaling76,82 leads to phosphorylation, dimerization and nuclear translocation of IRF336,37,86–91.
IRF3 dimers and IRF3/7 dimers are the major transcription factor complexes responsible for
expression of genes including type I IFN. TLR3 similarly removes inhibition of NF-kB which
permits it to translocate to the nucleus and bind its cognate regulatory elements92–95.
Once type I IFN (e.g. IFN-β) has been produced, it can act in an autocrine or paracrine
manner71,74,96,97. Type I IFN engages the type I IFN receptor, IFNAR64 (Figure 1.2). Downstream
of this receptor signaling is the JAK/STAT pathway64. JAK/STAT signaling culminates in the
phosphorylation of STAT1/2 and their complexing with each other and IRF9, forming the
12

interferon stimulated growth factor 3 (ISGF3)71,74,98,98. ISGF3 then translocates to the nucleus
where it stimulates the transcription of several hundred interferon stimulated genes (ISGs).
Three major classes of IFN are recognized, types I, II, and III99,100. The major class of IFNs
expressed throughout the body are type I IFN71,74,98,101, which include the several variants of IFNα and the singular IFN-β. IFN-λ is the only type II IFN discovered. IFN-γ is a type III IFN and its
expression is restricted to specific cell types32,102 The activation of type I IFN in the polarized type
II lung epithelial cells65 infected by RSV leads to a signaling cascade that catalyzes the expression
of a wide array of ISGs. IFN expression leads to activation and nuclear translocation of factors
including IRF-3 and NF-kB, which activate ISG expression36,37,86,89,91,103,104. The NS1 protein of
hRSV sequesters IRF-3 in the cytoplasm28,32, which prohibits IRF-3 from acting as a transcription
factor to stimulate ISG expression. However, even in the presence of a constitutively active,
nuclear-localized IRF-3 (IRF3-5D, discussed in detail below), IFN-β promoter driven reporter
expression is still lower in the presence of NS130, indicating that the cytoplasmic activities of NS1
do not fully explain its immune antagonist activities.

Chapter 2: Methods
Methods section adapted from Pei, Beri, et al. 39

Cells
Cell lines: Adenocarcinomic human alveolar basal epithelial (A549) and human embryonic kidney
epithelial (293T) cell lines were obtained from ATCC (CCL-185 and CRL-3216; Manassas, VA,
USA) and were maintained in complete Dulbecco’s modified Eagle’s medium (DMEM;
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ThemoFisher, 11965) supplemented with 10% heat-inactivated fetal bovine serum (FBS; SigmaAldrich, F4135). Cells were maintained at 37 °C with 5% CO2.

METHOD DETAILS

Plasmids. RSV NS1 was synthesized and subcloned into a pCAGGS vector containing either an
N-terminal Flag- or GFP- tag. Keap1105 was subcloned similarly. pCAGGS containing 3HAFLAG tagged NS1 (WT or Y125A) was used for chromatin immunoprecipitation and luciferase
reporter assays.

Viral infection. RSV strain A2 used in the study was obtained from ATCC (VR-1540; Manassas,
VA, USA). To determine the virus titers, cells cultivated in 24-well plates were inoculated with
10-fold serial dilutions of virus and incubated in 10% DMEM with methylcellulose at 37 °C for 7
d. Cells were fixed with cold methanol at −80 °C for 1 h. Methanol was removed and cells were
incubated with 5% milk blocking buffer at 37 °C for 1h. Followed by incubation of goat anti-RSV
(Fisher, AB1128MI) and HRP-labeled donkey anti-goat (Fisher, AP180PMI) antibodies. Cells
were incubated with 0.03% 4-Chloronapthol and 1% hydrogen peroxide at 25 °C. After 20 min
incubation, the plate was dried upside down and plaques counted. The multiplicity of infection
(MOI) was confirmed according to the virus titer from the plaque assay. RNA-seq data from
infections with RSV Y125A mutant NS1 was generated for Chatterjee et al.30 and re-analyzed here
(GSE99298).
For infection, A549 cells were grown to approximately 80% confluence in cell culture plates and
were infected with RSV at a MOI of 1. Mock infection was performed with phosphate buffered
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saline (PBS). After 1 hpi, the inoculum was removed by aspiration. Cells were washed twice with
PBS and incubated in complete medium at 37°C for different time points until harvesting. For
experiments with KPT-335 (verdinexor), A549 cells were infected with RSV at a MOI of 1 or
mock-infected with PBS. The inoculum was removed 1 hpi and cells were washed twice with PBS,
followed by replacement of complete medium supplemented with KPT-335 (1μM, RayBiotech
331-21369-1) or dimethyl sulfoxide (DMSO) at 37 °C for 24 h incubation.

Transfection
For ChIP: A549 cells were maintained in F-12K medium supplemented with 10% fetal bovine
serum and 5 mM penicillin–streptomycin at 37°C with 5% carbon dioxide. 293T (human
embryonic kidney cell line) were maintained in DMEM medium supplemented with 10% fetal
bovine serum and 5 mM penicillin–streptomycin at 37°C with 5% carbon dioxide. A549 cells
(10e^6) in 15cm plates were transfected with 20ug of pCAGGS vector containing a 3x HA-tagged
NS1 (HA-NS1) or 3x HA-Y125A NS1 (HA-Y125A) or no insert (empty vector) using
Lipofectamine transfection reagent (Invitrogen, Carlsbad, CA, USA).

Chromatin immunoprecipitation- (ChIP) seq and ChIP-qPCR. A549 cells were cross-linked
24 hours post-transfection at 70-90% confluence or 48 hours post-infection with hRSV. Crosslinking: Cells in 15cm plates were washed two times with PBS, incubated for 15 minutes with
1.25mM EGS (ethylene glycol-bis(succinic acid N-hydroxysuccinimide ester), Sigma, St. Louis,
MO, USA) in PBS, washed with 3 times PBS, incubated for 10 minutes with 1% formaldehyde
(Sigma, St. Louis, MO, USA) in PBS. Crosslinking was quenched with the addition of glycine
(125 mM final concentration, Sigma, St. Louis, MO, USA) for 5 minutes. Then cells were washed
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1 time with PBS. All cross-linking steps were performed at room temperature. Cells were scraped
from the plate in ice-cold PBS, aliquoted to 10e^6 cells per tube, snap-frozen on dry ice and stored
at -80C until sonication. Prior to sonication, cells were lysed in an SDS buffer (1% SDS, 10 mM
EDTA, 50 mM Tris [pH 8.0], dH2O) with EDTA-free protease inhibitors (Roche, France) for 20
minutes on ice, then chromatin was fragmented using a Bioruptor (Diagenode, Denville, NJ, USA)
to an average size of less than 300 bp. Ten percent of each sonicated sample was set aside for the
input sample and the remaining sonicated lysates were subjected to immunoprecipitation overnight
at 4°C with antibody conjugated to Protein-A Dynabeads. The following antibodies were used:
normal rabbit IgG (12-370, Millipore), anti-HA (ab9110, Abcam, Cambridge, UK), and Mediator
(TRAP1/CRSP220, A300-739A, Bethyl Laboratories, Montgomery, TX, USA); 2.5ug per 10e6
cells. Chromatin-IP-bead mixtures were then washed three times with buffers: low-salt buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris [pH 8.0], 150 mM NaCl, dH2O), highsalt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris [pH 8.0], 500 mM NaCl,
dH2O), LiCl buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris [pH
8.0], dH2O), and 1X Tris-EDTA buffer, and eluted with an SDS buffer (1% SDS, 0.1 M NaHCO3,
dH2O). Chromatin cross-links were reversed in eluted ChIP and input samples by overnight
incubation with 5M NaCl at 65°C and DNA was isolated using PCR MinElute spin purification
columns (Qiagen) as per manufacturer's instructions. At least 10 ng of ChIP or input DNA was
submitted for indexed library preparation to the Genome Technology Access Center at Washington
University in St. Louis. Samples were indexed and pooled (9-11 per lane) and subjected to 50 bp
single-end sequencing according to the manufacturer’s protocol (Illumina HiSeq3000, San Diego,
CA, USA). ChIP-qPCR was performed with equal volumes of eluted DNA isolated as for ChIPseq
with

the

following

primers:

IFITB:
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GGTATGCCGACCTTGAGAGAG

and

TTCCCACTAAGGGTCCTGTTC;

IFITC:

CTGTGTCTCTGCTGTTCCGA;

IFITD:

AGCAGTCCTGGTTCTGTGAG;

GAPDH:

TGATGCGTGCCCTACTCTC

and

GGCTGTTTCCTTATTGTTGCTCT

and

CGCAGAGCCTCGAGGAGAAG

and

ACAGGAGGACTTTGGGAACGAC.

RNA-seq
Infected cells were harvested and RNA was extracted using the Qiagen RNA Easy kit (Cat. No. /
ID: 74004) and 500ng submitted to the Genome Technology Access Center at Washington
University in St. Louis. Samples were indexed and pooled (3 per lane) and subjected to 100 bp
paired-end sequencing according to the manufacturer’s protocol (Illumina HiSeq3000, San Diego,
CA, USA).

Luciferase reporter assays. Luciferase reporter assays were performed as previously described106
with the following modifications. 2.5x10^4 293T cells per well of a 96-well plate were transfected
with pNL1.1.TK (control NanoLuc vector, Promega, Madison, WI, USA), plus wild-type or
Y125A mutant NS1 or empty vector (pCAGGS), with or without 4ug/ml poly(I:C) (for IFIT locus
wide luciferase assay) or 14.3 ng/ml (for all other luciferase assays); IFN-β 1000 IU/ml; or TNFα 20 ng/ml 5 hours before harvest (Sigma, St. Louis, MO, USA), plus luciferase reporter plasmids:
minimal promoter pGL4.23 (Promega) or ISRE reporter pGL4.45 (Promega) or minimal promoter
pGL4.23 (Promega) with one of the NS1 binding regions cloned in, and with the control reporter
NanoLuc pNL1.1 (Promega). 293T cells were subjected to luciferase assay 24 hours posttransfection (triplicate wells per condition, 96-well plate). The Promega Nano-Glo system
(#N1110) was used to measure the firefly and NanoLuc (control) luciferase activity for each well
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according to the manufacturer’s instructions in a BioTek Cytation5 plate reader. All experiments
were performed at least twice.

ChIP- and RNA-sequencing analysis. Reads were aligned to hg19 with bowtie2 (v2.2.5) with
default settings107. Peaks were called with HOMER (version v4.10.1) with the settings tbp = 1 and
findPeaks cmd = findPeaks ns1_ha_align_tbp1/ -style factor -o auto -i ns1_input_align_tbp1/108.
RPKM normalized genome browser tracks were created with deepTools (v3.1.0) bamCoverage
utility with settings--binSize10--extendReads150—normalize using RPKM and visualized on the
UCSC genome browser 29106570. ChIPQC (v1.14.0) was used for quality control109. The
ChIPSeeker R package (v1.16.1) and HOMER were used to annotate peaks108,110,111.
For new RNA-seq data acquired for this paper (0 h.p.i., 24 h.p.i., 48 h.p.i.), basecalls and
demultiplexing were performed with Illumina’s RTA version 1.9 and bcl2fastq2 software with a
maximum of one mismatch in the indexing read. RNA-seq reads were then aligned to the Ensembl
release 76 primary assembly with STAR version 2.5.1a112. Gene counts were derived from the
number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.6-p5 (Liao
et al., 2014). Isoform expression of known Ensembl transcripts were estimated with Salmon
version 0.8.2113. Sequencing performance was assessed for the total number of aligned reads, total
number of uniquely aligned reads, and features detected. The ribosomal fraction, known junction
saturation, and read distribution over known gene models were quantified with RSeQC version
2.6.2114. All gene counts were then imported into the R/Bioconductor package EdgeR115, and TMM
normalization size factors were calculated to adjust for samples for differences in library size.
Ribosomal genes and genes not expressed in the smallest group size minus one sample greater than
one count-per-million were excluded from further analysis. The TMM size factors and the matrix
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of counts were then imported into the R/Bioconductor package Limma116. Weighted likelihoods
based on the observed mean-variance relationship of every gene and sample were then calculated
for all samples with the voomWithQualityWeights117,118. The performance of all genes was
assessed with plots of the residual standard deviation of every gene to their average log-count with
a robustly fitted trend line of the residuals. Differential expression analysis was then performed to
analyze for differences between conditions and the results were filtered for only those genes with
Benjamini-Hochberg false-discovery rate adjusted p-values less than or equal to 0.05. Heatmaps
and volcano plots were generated with R packages heatmap2 and ggplot2. Genotify (v1.2.1) was
used for manual gene curation55. Graphing and statistical analyses were performed using the R
ggplot2 (3.2.1) and stats (3.4.1) packages and with Graphpad Prism version 8.2.1.

ChIP-qPCR analysis. Triplicate PCR wells were averaged and input wells were also scaled to
100% (10% of total input chromatin had been set aside from each sample prior to ChIP): input Ct
value -3.322. Percent input for each ChIP sample was calculated as % input =100 * 2^([scaled
input]-[sample]). Log2 fold change was plotted in figure by 2^(% input-ChIP sample/% input
IgG).

Luciferase reporter assay analysis. The average ratios of the firefly to NanoLuc luciferase
replicate values for each condition were compared to the average ratio for the minimal promoter
reporter to determine relative luciferase activity. Statistical analyses were performed using
Graphpad Prism 8. A p value < 0.05 was considered statistically significant. For all graphs, mean
values ± standard deviation (SD) are shown.
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Statistical analysis. Unless otherwise indicated, statistical analyses were performed using
Graphpad Prism 8. A p value < 0.05 was considered statistically significant. For all graphs, mean
values ± standard deviation (SD) are shown.
Table 2.1 Primers used to clone NS1 bound sites into pGL4.23
chr10NB353

CGCGgagctcAGCCCAAGGTTGTAAACCACT

IFIT_D_For_1

176
chr10-

NB354

TATAagatctCCATCTCAGGCTCAGGTCAG

IFIT_D_Rev_1

176
chr10-

NB355

CGCGgagctcATTGCAGGTCTCAAGCCGTTA

IFIT_C_For_1

226
chr10-

NB356

TATAagatctGGAAATAGCTGCACACAGGG

IFIT_C_Rev_1

226
chr10-

NB357

CGCGgagctcCCTGGGAAGGAACACCACAC

IFIT_B_For_1

385
chr10-

NB358

TATAagatctTTGAAGGCAGTTTTAGGGGCA

IFIT_B_Rev_1

385
chr10-

NB359

CGCGgagctcACCCCTCATACAATCCTGCC

IFIT_A_For_1

214
chr10-

NB360

TATAagatctGGTCTTCCAGGTCTGAAGCAA

IFIT_A_Rev_1

214

ISG20_ISRE_LUC
NB505

CGCGgctagcCTAGCCACTCCCACCACAAG

20

_F1

chr15-12

ISG20_ISRE_LUC
NB506

NB509

NB510

TATActcgagCCCCATCCCCTGCCTTACC

_R1

chr15-12

IFIT3_ISRE_LUC

chr10-

CGCGgctagcATTGCAGGTCTCAAGCCGTTA

_F1

226

TATActcgagGCCTGCACAGTAAGAAACTCA

IFIT3_ISRE_LUC

chr10-

AC

_R1

226

CGCGgctagcGTAGCAGGCTCCAGAAGTTAG
NB511

TTGTG

NFKB_incl_F

chr15-12

NB512

TATActcgagCAAGTGAAGTCAGGGGCGGA

NFKB_incl_R

chr15-12

CGCGgctagcAGTCCTGGGGATGTTTATTCTC
NB513

TG

ISRE_incl_F

chr15-12

NB514

TATActcgagCATCGGCATCCCGACCCTG

ISRE_incl_R

chr15-12
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Chapter 3: NS1 is distributed throughout the genome at several hundred discrete genomic
regulatory elements and physically associates with the transcriptional regulatory complex
Mediator
3.1 Work by several investigators in our groups indicates that NS1 partitions to the nucleus and
associates with components of the Mediator complex39

Figure 3.1. NS1 is found in the nucleus of
RSV infected human airway epithelial cells
and associates with components of the
nuclear-localized Mediator complex. A and
B, Low and high power magnified images of
mock or RSV infected hTECs differentiated
using air-liquid interface culture technique
were stained for DAPI (blue, nuclear stain),
ciliary marker anti-acetylated tubulin (red, acα-tubulin), and either hRSV nucleoprotein or
NS1 as labeled (green). Scale bar is 10 µm. C,
Affinity purification followed by mass
spectrometry identified interacting proteins of
NS1. Volcano plot shows fold change over
unrelated control (n=3) and p-value.
Significant interactors in red, other in blue, and
depleted in grey. Adapted from Pei, Beri, et al.
Cell Reports 2021
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NS1 has several demonstrated immune antagonist functions in the nucleus as described in
the Introduction. Immunofluorescence of primary human tracheobronchial epithelial cells (hTECs)
differentiated into ciliary cells using air-liquid interface (ALI)119,120 was performed to detect RSV
proteins nucleoprotein or NS1 after infection. Differentiated cells were fixed and probed with antiacetylated tubulin as a molecular marker of cilia, an organelle specific to ciliated epithelial cells,
and DAPI as a nuclear stain. Antibody to hRSV nucleoprotein detected nucleoprotein localized to
the cytoplasm, in a pattern representative of localization in inclusion bodies, wherein RSV is
thought to replicate and avoid immune detection121–123. An antibody to NS1, a unique reagent
recently generated by the Leung group39, detected NS1 throughout the cell, in the nucleus as well
as cytoplasm, but excluded from nucleoli (Figure 3.1A, B). Work by the Leung group (Figure
3.1C) and others38,39 using affinity purification followed by mass spectrometry (AP/MS) showed
that several components of the nuclear-localized Mediator complex, a central transcriptional
regulatory complex, associate with NS1. Given this unexpected result, the Payton and Leung
groups continued to investigate a potentially novel nuclear role for NS1.
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B

A

Figure 3.2. NS1 partitions to the soluble nuclear and chromatin fractions and coimmunoprecipitates with Mediator from the soluble nuclear fraction. A, Subcellular fractionation
followed by Western blot for NS1 and host proteins (Jacqueline Payton). U, unfractionated; M,
membrane associated; Cy, cytoplasmic; SN, soluble nuclear; Ch, chromatin. B, Western blots show coimmunoprecipitation of MED components MED1, MED14, and MED25 with an antibody to FLAGNS1 from transfected A549 cells (Jingjing Pei). WCL, whole cell lysate. Adapted from Pei, Beri et al Cell
Reports 2021

3.2 NS1 partitions to both soluble nuclear and chromatin associated fractions and coimmunoprecipitates with several subunits of the Mediator complex
To confirm that transfected NS1 partitions to the nucleus, my advisor Dr. Jacqueline Payton
performed subcellular fractionation followed by Western blotting (Figure 3.2A) for NS1transfected A549s. The blot demonstrates fractionation of Mediator and CTCF, which are nuclear
and chromatin-associated proteins, and tubulin, a cytosolic protein, into the expected fractions.
NS1 is detected throughout the cell including in the cytosolic, soluble nuclear, and chromatin
fractions. The association between NS1 and Mediator was further confirmed by coimmunoprecipitation of transfected FLAG-NS1 with Mediator from the soluble nuclear fraction
of A549s (Figure 3.2B).
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3.3 NS1 enters the nucleus via active transport
NS1 is a protein of only 15.8 kDa, which is below the size limit of passive diffusion into
the nucleus39. To test for active transport of NS1, Jingjing Pei of the Leung group performed
immunofluorescence of GFP-tagged NS1 (Figure 3.3)39. Addition of the GFP tag increased
molecular weight to ~ 42 kDa, the purpose being to increase the weight of NS1 to prevent passive
transport. The cytoplasmic Cullin ligase adaptor protein Keap1 was used as a control. GFP-tagged
Keap1 did not partition to the nucleus, while GFP-tagged NS1 did39. These data suggest that NS1
utilizes active transport to enter the nucleus. Further studies to elucidate the import mechanism are
ongoing in the Leung lab. This section concludes the relevant experiments conducted by others
within our groups.
A

Figure 3.3. GFP-tagged
NS1 partitions to the
nucleus of hRSV infected
cells. Confocal micrographs
of A549s transfected for 24
hours with (A) GFP-tagged
Keap1 or (B) NS1 and fixed.
Cells were stained for DAPI
(blue), anti-MED1 (red), or
GFP (green). Fluorescence
intensity
across
a
representative slice of the cell
is shown to the right. Adapted
from Pei, Beri, et al. Cell
Reports 2021

B
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3.4 Chromatin immunoprecipitation for Mediator identified 21,020 binding sites genome wide
The studies above show that NS1 undergoes active transport into the nucleus and associates
with chromatin and Mediator subunits. We next asked whether NS1 has a genome-wide chromatin
binding profile. This protein has not previously been tested using ChIP-seq. In contrast, ChIP-seq
to determine Mediator binding has been performed such that validated antibody and sequencing
datasets are available124. Therefore, I carried out Mediator ChIP-seq as quality control to ensure
my technique was working as well as to test for its genome-wide chromatin binding profile for
hypothesis testing. I mapped Mediator binding with α-Med1 antibody in cells transfected with HANS1 or mock transfected and in cells infected with hRSV A2 or mock infected. Sequencing was
performed at Washington University Genome Technology Access Center (GTAC) and reads were
aligned to the human genome version hg19. Using the HOMER software suite, I used the findPeaks
command line tool to call peaks.
I next validated the Mediator ChIP-seq dataset against previously published independent
research. I searched the literature for Mediator ChIP datasets and downloaded a dataset from the
Bilodeau group at the Université Laval in Canada124. They carried out ChIP-seq on three cell lines,
including the A549 human lung epithelial cell line I used in my ChIP-sequencing studies, also
aligned to hg19. Their group also used the same antibody against MED1, Bethyl A300-793A, that
I used in my studies. However, I used EGS and formaldehyde to crosslink while they used
Figure 3.4 Overlap of 21,020 Mediator peaks in my
dataset with previous published data (Bilodeau group).
Dark blue, direct overlap of one or more nucleotide (9%);
light blue, proximity of <20 kb; grey, all other Mediator
peaks in my dataset.
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formaldehyde only. From the Gene Expression Omnibus (GEO) repository, I downloaded the peak
file generated by this group from their raw data. As they used a different peak calling algorithm,
MACS2, with different specifications, the peaks from their dataset have different characteristics.
In some cases, wider peaks in their dataset are called as two closely spaced peaks in my dataset.
Some peaks called in their dataset were not identified in mine, and vice versa; however, 1,879 of
the 21,020 peaks (8.9%) that I had identified directly overlapped peaks in the Fournier et al. dataset
by at least one nucleotide, with 6,240 (30%) are within 20 kilobases of their peaks (Figure 3.4).
With Mediator binding sites mapped genome-wide, I next evaluated NS1 binding genome-wide.

3.5 NS1 binds 1,756 sites throughout the genome at transcriptional regulatory elements
To map genome-wide chromatin binding of NS1, I used a 3HA-tagged NS1 construct to
transfect A549 human lung epithelial cells. I used anti-HA to immunoprecipitate NS1 in the
transfected cells and in empty vector-transfected cells as a negative control given the lack of an
available α-NS1 antibody. I found that NS1 binds 1,756 discrete loci (Figure 3.5A). Forty-two
percent coincide with Mediator binding sites in my dataset, including from NS1-transfected,
empty-vector-transfected, RSV infected, and mock-infected cells (Figure 3.5A) with the majority
overlapping at least one enhancer element125. Using bedtools, I found that 81% of NS1 sites lie
within 10 kb of at least one gene. To calculate this, I compared the genomic coordinates of NS1
binding sites with the start –10kb and end +10kb of all genes (Homo sapiens
(human) genome assembly GRCh37 (hg19) from Genome Reference Consortium126) to identify
potential overlaps. This analysis mapped NS1 binding sites located within or near promoter and
enhancer elements that may modulate transcription of these neighboring genes, although it was
not a functional confirmation.
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Figure 3.5. ChIP-sequencing of NS1 reveals binding sites associated with Mediator, transcriptional
regulatory elements, and differentially expressed genes during hRSV infection. A, Pie chart shows total
number of NS1 peaks called (red) and percent that overlap at least one Mediator peak (grey). B, Number ofNS1
sites (total of 1,756) that overlap the indicated genomic element. C, Bar graph shows genomic annotations of NS1
only (red), Mediator only (grey) or both (white) sites overlapping different genomic elements labeled on X axis.
D, NS1 peaks, Mediator peaks, or NS1-Mediator overlapping peaks annotated as in (C) but overlapping all
enhancers or lung specific enhancers; E, As in D but for all promoters or promoters of differentially expressed
genes (DEGs). Adapted from Pei, Beri, et al. Cell Reports 2021

While forty percent of NS1 sites overlapped Mediator sites, a closer evaluation of the genomic
annotations revealed important differences. We compared NS1 unique binding sites, Mediator only
binding sites, and sites with NS1 and Mediator binding sites overlapping by at least one nucleotide.
While both NS1 and Mediator are enriched at promoter and 5’ UTR sites, Mediator alone is more
enriched than NS1. At exons, Mediator but not NS1 is enriched (Figure 3.5C). We also quantified
the percent of NS1 only, Mediator only, and combined binding sites that overlap enhancer
elements. Seventy-three percent of NS1 binding sites overlapped enhancers, of which 95% were
in lung tissue enhancers. In comparison, only 40% of Mediator sites overlapped enhancers, of
which 82% were lung enhancers. For promoters, Mediator only peaks were found more frequently
(40%) than NS1 only (17%) and NS1-Mediator (20%) binding sites. However, 34% of genes
differentially expressed during RSV infection harbor an NS1 peak, a substantial increase over total
promoters (10%). In comparison, there is a smaller proportion of differentially expressed genes
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with Mediator peaks compared to total promoters (26% versus 32%). These data show that NS1
binding is enriched in transcriptional regulatory elements and that it preferentially binds near the
promoters of genes that respond to RSV infection. Thus, I next evaluated the association of NS1
binding sites with specific genes differentially expressed during hRSV infection.

Figure 3.6. NS1 ChIP-seq reveals binding sites associated with Mediator, transcriptional regulatory elements,
and differentially expressed genes during hRSV infection. A, volcano plot of gene expression in A549s at 96
h.p.i vs mock infection with hRSV bearing wild-type NS1. DEGs are in blue, and DEGs within 10 kb of an NS1
binding site are in red. B, same as (A) but comparing hRSV infection bearing NS1 Y125A to mock. C, heat map of
differentially expressed genes within 10 kb of an NS1 peak in the indicated condition. Adapted from Pei, Beri, et

al. Cell Reports 2021

3.6 NS1 peaks are enriched within 10 kilobases of genes differentially expressed during hRSV
infection with WT but not Y125A NS1
To query for an association between NS1 binding sites and differentially expressed genes
during hRSV infection required a relevant differential gene expression dataset. I used the
DESeq2127 package to generate differential expression data with RNA sequencing data128 from
A549 cells 96 hours after infection with WT hRSV or mock infection. Comparison to the NS1
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ChIP-seq

data

enrichment
differentially

shows
of

expressed

genes (DEGs) within 10
kb

of

a

NS1

peak.

Specifically, 30% of genes
Figure 3.7 Immune response gene sets were enriched near NS1
peaks Reactome database gene sets related to the immune system
(A) and interferon signaling (B) were among those enriched in
genes within 10 kb of an NS1 peak that were differentially
expressed between WT hRSV infection and mock infection using
GSEA.

within 10 kb of at least
NS1 peak were DEGs
(differential expression =
fold change > +/- 2;

Benjamini-Hochberg adjusted false discovery rate < 0.05, as compared to about 25% of genes
overall. The volcano plot in Figure 3.6A shows genes that are differentially expressed between
wild type and mock RSV infection at 96 hours post-infection. Genes within 10 kb of an NS1 peak
are highlighted in red, demonstrating that a significant portion are among the most highly
differentially expressed genes. In contrast, the gene expression profile of Y125A NS1 RSV
(Figure 3.6B, C) infected cells is more like that of mock infected cells than that of WT NS1 RSV
infected cells, with substantial reductions in fold change differences and significance values
(Figure 3.6A, C).
Of the host genes with altered expression during hRSV infection, many such as IRF2 and IFIT2
are significantly up-regulated in WT NS1 hRSV infection (IRF2: log2 fold change 0.996, adjusted
p-value 1.3e-4; IFIT2: log2 fold change 3.7, adjusted p-value 6.9e-21) but dramatically less so in
Y125A NS1 hRSV infection (IRF2: log2 fold change 0.49, adjusted p-value 0.25; IFIT2: log2
fold change 0.6, adjusted p-value 0.48). I used gene set enrichment analysis (GSEA) to analyze all
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genes differentially expressed in WT NS1 infection versus mock and within 10 kb of an NS1 peak.
GSEA identified several enriched biological pathways, including innate immune system and
interferon signaling (Figure 3.7) that were enriched in this subset of genes. Thus, the differential
gene expression profile of hRSV infected A549s was associated with NS1 bound regulatory
elements.

3.7 A cluster of NS1 binding sites at the IFIT locus was validated via ChIP-qPCR for binding by
both WT and Y125A NS1
To validate the ChIP-seq data, I focused on NS1 binding sites near genes with altered
expression during hRSV infection. The most promising of these was the IFIT locus, in which I
identified four NS1 binding sites near four IFIT family genes. Site A is at a distal enhancer; site B
is at the 3’ UTR of IFIT2; site C is at the promoter of IFIT3; and site D is just upstream of the
IFIT1B promoter (Figure 3.8A). The IFIT (interferon induced proteins with tetratricopeptide
repeats)55 genes are a cluster of relatively recently diverged interferon stimulated genes in the same
genomic neighborhood. HOMER called four NS1 binding sites, out of which two overlap Mediator
binding sites in the same condition (NS1-transfected cells). Comparison of the NS1 and Mediator
binding sites from my dataset with publicly available ENCODE datasets shows that general
transcriptional coactivators such as P300, and tissue specific transcription factors may be detected
in the same region (Figure 3.8A).
By ChIP-qPCR, I validated WT NS1 chromatin binding at three IFIT loci. I did not identify
reliable and specific qPCR primers for peak A, so I assayed peaks B, C, and D (Figure 3.8B).
DNA immunoprecipitated with HA tagged NS1 or with IgG was normalized to input for each
condition. 3HA-tagged WT NS1 was enriched vs. IgG at regions C and D. I next asked whether
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NS1 Y125A binds chromatin at these same regions. I found that Y125A NS1 bound DNA at least
as well as WT NS1 at each of the three IFIT peaks B, C, and D.
My ChIP-seq and qPCR work described in this chapter builds on the work of my
collaborators that established nuclear localization, chromatin associated subcellular partitioning,
and association with Mediator complex subunits. Taken together, these findings suggest a role for
the hRSV NS1 protein in modulating transcriptional regulation at chromatin associated regulatory
elements.
Figure 3.8. NS1 binding sites throughout
the
IFIT
locus
overlap
host
transcriptional regulatory factors, and
both WT and Y125A NS1 bind at most of
these loci. A, NS1 binding sites at the IFIT
locus are labeled A through D above the raw
read tracks in the UCSC Genome Browser
and in red below them. Mediator tracks of
raw data and called peaks are shown in blue.
Host transcriptional regulators CBP/p300,
STAT1, STAT2, STAT3, and IRF1 peaks
from ENCODE (Sloan et al 2016) are shown
below. B, ChIP-qPCR was performed on
samples transfected with either 3HA-FLAG
NS1 WT or 3HA-FLAG-NS1 Y125A. The
results for HA-NS1 pulldown and IgG
pulldown at IFIT loci B, C, and D are shown
as a percent of input. Adapted from Pei,

Beri, et al. Cell Reports 2021

3.8 Discussion
NS1 is a multifunctional interferon antagonist with several documented cytoplasmic
functions28,32,75,129. The findings that NS1 partitions to the nucleus and associates with chromatin
and several components of Mediator, a known transcriptional regulatory complex, support an
additional nuclear role for NS1. The manifold roles of Mediator include its function as a
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component of the pre-initiation complex40,44, its role in bringing enhancer and promoter elements
into closer proximity45,124,130, and a role of the CDK8 domain of Mediator that is mutually
exclusive with its association with RNA polymerase II131–134.
Gene expression is regulated tightly by multiple interacting pathways135–137. Such tight
regulation is a prominent feature of homeostasis and inappropriate deviations from the basal level
of gene expression are associated with disease states (e.g., chronic inflammatory disease138–140,
cancer141–143). While the cytoplasmic activities of NS1 enable it to suppress immune response
proteins, our data demonstrate that NS1 may also function to suppress the production of immune
proteins at the level of transcription.
The presence of NS1 in the chromatin-associated fraction and in association with the
Mediator suggests such a role in the modulation of gene expression. To participate in modulation
of gene expression, chromatin-associated NS1 would be expected to be enriched at regulatory
elements. These are non-coding regions which by merit of their sequence permit the binding of
specific transcriptional regulatory proteins. Indeed, our chromatin immunoprecipitation of NS1
found it was bound at many transcriptional regulatory elements, both enhancers and promoters,
and often overlapped Mediator binding sites. Together, these data demonstrated that NS1 may play
a role in altered gene expression during hRSV infection via interaction with chromatin associated
host transcriptional regulators at these regions.
Like the genomic annotations for the Mediator complex, NS1-only and NS1-Mediator
binding sites are enriched at promoter and 5’ UTR elements. These regions are required for
transcription of the gene under their control. The pre-initiation complex (PIC) and RNA
polymerase II assemble at these regions. As NS1 is present at several promoter elements, it may
interfere with PIC assembly, or prevent RNA Polymerase II from carrying out its elongation
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function when present at the 5’ UTR, as well as at genic elements such as exons and introns at the
5’ end of the gene. NS1 promoter peaks are enriched near differentially expressed genes during
hRSV infection, so it is possible that NS1 alters viral responsive changes in host gene expression
under the control of these elements. NS1 is also enriched at lung specific enhancer elements. For
enhancers that are dependent on innate immune signaling, the presence of NS1 may alter the
kinetics of enhancer activation. Furthermore, in its capacity as a binding partner of the Mediator
complex, NS1 may interfere in its function in bringing enhancers and promoters in proximity at
actively transcribed genes. As GSEA indicates that enriched biological functions at NS1 peak
proximal genes include interferon signaling and innate immune response, expression of such viral
response related genes may be altered at regulatory elements at which NS1 is bound.
For instance, NS1 binding sites were identified at several regulatory elements in the IFIT
locus. During hRSV infection the genes within this locus are differentially expressed, and the
enrichment of NS1 binding sites at regulatory elements in this region suggests that NS1 plays a
role in the modulation of their expression. As innate immune response genes and interferon
stimulated genes, the gene products contribute to the antiviral state144–146. Disrupting the
expression of such genes could prevent the cell from fully adopting an antiviral state.
Previous work showed that cells infected with recombinant hRSV containing NS1 Y125A
mutant exhibited fewer differentially expressed genes and these had lower fold change throughout
infection128. One potential explanation for this would be that the NS1 Y125A mutation negatively
impacts NS1’s ability to bind chromatin. However, ChIP-qPCR for the IFIT loci for both WT and
Y125A 3HA-tagged NS1 showed that NS1 Y125A binds chromatin at least as well as WT NS1 at
these regions. Another possibility is that Y125A NS1 has altered capacity to interact with key
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transcriptional regulatory proteins compared to WT hRSV. Future experiments such as ChIP-seq
and AP-MS for Y125A NS1 are needed to address these questions.
Signal-dependent gene expression relies on tight regulation to appropriately respond to
stimulus88,97,147. The predominant value of the innate immune system, specifically the interferon
signaling pathway that is induced in response to viral infection, lies in its capacity to rapidly detect
and respond to infection64. Impeding this rapid response is a major function of NS1, documented
to act in the cytoplasm as an interferon antagonist26,28,30,33,34,49. In the nucleus, targeted antagonism
of host innate immune response genes would add another dimension to this function. Potentially,
transcription of genes encoding products required for hRSV life cycle functions might be
unaffected or even induced further while transcription of genes encoding innate immune response
factors might be suppressed.
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Chapter 4: In the presence of NS1, gene expression is altered in several conditions relevant to the
innate immune response
4.1 Genomic regulatory elements overlapping NS1 binding sites drive altered transcription in the
presence of NS1
The genome-wide chromatin binding studies showed that NS1 often overlaps regulatory
elements, transcription factor binding sites, and Mediator binding sites, suggesting that this viral
protein may impact host transcriptional regulation. Therefore, I next sought to define the functional
effect of NS1 on gene expression. Given that Mediator does not coincide with all NS1 binding
sites, I hypothesized that NS1 may interact with other transcription factors and/or transcriptional
regulatory proteins. Indeed, I identified overlap of IRF, STAT, and p300 binding sites with NS1
peaks in the IFIT locus (Figure 3.8).
Therefore, I subjected all NS1 binding sites to transcription factor motif analysis and
comparison to publicly available transcription factor ChIP-seq data. I used HOMER
findMotifsGenome to identify transcription factor binding motifs enriched at the NS1 peaks.
Although no single transcription factor dominated the enrichment results, motifs for the AP-1 (pvalue 1e-373, 13-fold increase over background) and FOXA1 (p-value 1e-433, 6-fold increase
over background) transcription factors were identified. While highly enriched, these transcription
factors are ubiquitous and not specific to innate immune response. Enriched motifs for
transcription factors involved in innate immune response included STAT3/IL-21 (p-value 1e-3,
1.4 fold increase over background), CHOP (p-value 1e-12, 2.7 fold increase over background),
and STAT1 (p-value 1e-2, 1.5 fold increase over background).
As queries using HOMER gave in silico predictions, I next queried Factorbook148, a repository
of publicly available transcription factor binding datasets, for ChIP-seq datasets for relevant
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transcription factors. Because NS1 is a multifunctional interferon antagonist22,28–30,32,33,129, I
searched for transcription factors within the STAT and IRF family. These are mediators of
interferon induction and signaling pathways36,37,69,71,149.
To identify the ChIP-seq datasets most relevant to my project, I sought ChIP-seq datasets
performed in A549 cells that were used in my NS1 and Mediator ChIP-seq experiments. I did not
find datasets for innate immune response transcription factors STAT1, STAT2, STAT3, STAT5A,
and IRF3 and regulatory factors PGC1A and CEBPB in A549s, but rather used existing datasets
from HeLa, IMR90, K562, and HepG2 cell lines. I searched for STAT and IRF family transcription
factors as they are involved in the innate immune response (Figure 1.2). PGC1A is a component
of the epigenetic silencing Polycomb complex150 . Next, I used bedtools window to identify peaks
in my NS1 ChIP-seq dataset associated via proximity with significantly upregulated genes in
hRSV infection. I used window rather than intersect, the standard bedtools function used for
identifying overlapping genomic features, because regulatory elements may be some distance
away from the genes for which they control expression. Starting with a 1-kb window upstream and
downstream of all genes, I tested a 5-kb window, 10-kb window, and 20-kb window. After
increasing past 10 kb, I found that there were few additional NS1-gene pairs identified.
The four IFIT locus NS1 peaks were noteworthy, as in addition to sequencing data, I had
validated binding at three of the four (B, C, and D) via ChIP-qPCR for both WT and Y125A NS1.
Thus, I cloned the regulatory elements containing these peaks into luciferase reporter plasmids to
test whether these regulatory elements drove altered gene expression in the presence of NS1.
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4.2 Luciferase reporter assay was used to test changes in transcription driven by bound regulatory
elements in the presence of NS1
Given that NS1 associates with Mediator and is bound at regulatory elements enriched near
genes differentially expressed during hRSV infection, the evidence to this point suggests that NS1
may alter gene expression controlled by regulatory elements at which it binds. The luciferase
reporter assay is commonly used to test the effect of a stimulus or other molecular factors on

Figure 4.1. Luciferase assay workflow. A 400-1000 base pair region encompassing an NS1
binding site was cloned into the pGL4.45 firefly luciferase plasmid upstream of the minimal
promoter (minP). A plasmid constitutively expressing NS1 (or empty vector), a constitutively
active nanoLuc expressing plasmid (pNL1.1.TK), an immune stimulus (or none), and the
experimental luciferase plasmid were transfected into 293Ts. 24 hours later, firefly
luminescence and nanoLuc luminescence were read on a BioTek plate reader with Gen5
software (version 3.08). The ratio of firefly to nanoLuc was taken to normalize for transfection
efficiency and the ratio for each well was compared to that for the minimal promoter in the
same condition.
transcription under the control of a known regulatory element or to compare transcription driven
by different regulatory elements. Thus, I used a luciferase reporter assay to test whether
transcription driven by IFIT locus regulatory elements was altered in the presence of NS1 (Figure
4.1). As known NS1 functions antagonize the innate immune response, and infections with virus
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bearing a3 helix structure-based mutants of NS1 were attenuated in IFN-competent but not IFNnull cells30, the nuclear function of NS1 is likely to be associated with the type I IFN response.
Therefore, I tested the effect of NS1 on reporter gene expression in stimulated cells, having
activated the signaling pathways culminating in upregulation of innate immune response genes.
To stimulate cells, I first used polyI:C, a double stranded RNA mimic that strongly induces
signaling through both RIG-I and TLR376,93. Both the ISRE and NF-kB regulatory elements are
bound by transcription factors involved in type I IFN production71,96,97,147, as IRF family members
and NF-kB are activated downstream of double-stranded RNA detection, but ISRE motifs alone
are bound by ISGF3 in the induction of interferon stimulated genes (Figure 1.2).

Figure 4.2. Transcription driven by NS1 binding sites in IFIT locus regulatory elements
is decreased in the presence of NS1. Bar graph shows luciferase activity for the ISRE-5x
plasmid (positive control) and regulatory elements cloned from NS1 binding sites in the IFIT
locus (see locus map). Cells were transfected with the indicated reporter plasmid, control
luciferase plasmid (nanoLuc), empty vector (EV) or NS1 plasmid, and stimulated with polyI:C.
Twenty-hour hours later, luciferase luminescence was measured. Fold change = (ratio of firefly
ISRE-5x or IFIT plasmid to nanoLuc) / (ratio of minimal promoter reporter plasmid to
nanoLuc). EV, pCAGGS empty vector. NS1, pCAGGS-3HA-FLAG-NS1 WT. Representative
of two independent experiments. Unpaired t-test, * p < 0.05, ** p < 0.005, ns, not significant.
Bars show mean with standard deviation. Adapted from Pei, Beri, et al, Cell Reports 2021
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4.2 Reporter expression driven by IFIT locus regulatory elements is decreased in the presence of
NS1
Using luciferase reporter assays, I tested the regulatory impact of NS1 on four NS1 bound
regulatory elements throughout the IFIT locus. I cloned a several hundred base pair region
encompassing each NS1 binding site upstream of a minimal promoter in a luciferase reporter
plasmid. In triplicate wells of a 96-well plate, I transfected 293Ts with 4 ug/ml polyI:C, a pGL4based firefly luciferase reporter plasmid, the transfection control plasmid pNL1.1.TK, and a
plasmid expressing NS1 or an empty vector. Twenty-four hours after plating, I read the luciferase
luminescence on a plate reader. I took the ratio of firefly luciferase activity to the nano luciferase,
the latter of which was driven by a constitutive TK promoter and functioned to normalize for
transfection efficiency. I next normalized this ratio to the baseline luciferase activity level of the
minimal promoter, which was the same backbone plasmid into which each NS1 binding site region
was cloned. For each condition, I calculated these ratios for cells co-transfected with empty vector
or NS1.
As a positive control, I used the interferon stimulated regulatory element repeat (ISRE-5x)
which contains an optimized commercially available promoter with the ISRE motif repeated five
times. It is highly responsive to polyI:C stimulus151–153. For the ISRE-5x promoter under these
conditions, there was not a significant change in expression upon the addition of NS1 (Figure 4.2).
However, later experiments using 14.3 ug/ml polyI:C did yield upregulation in ISRE-5x mediated
reporter expression suggesting that more stimulus was required to observe a strong activation.
For IFIT peaks A, C, and D, there was a significant decrease in expression in the presence of
NS1. A is at a distal enhancer nearest to IFIT2 and D is at an enhancer just upstream of the IFIT1B
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promoter, while C overlaps the IFIT3 promoter. This data shows that gene transcription is
significantly lower in the presence of NS1 when driven by IFIT genomic regulatory elements at
which NS1 binds, including both promoter and enhancer elements.

4.3 Both WT and Y125A NS1 decrease transcription driven by optimized ISRE-5X and NF-kB RE4X regulatory elements
Having shown that transcription driven by NS1-binding genomic regulatory elements is
decreased in the presence of WT NS1, I next tested the effect of the Y125A point mutant of NS1.
Briefly, infection with recombinant RSV containing this variant of NS1 substantially reduces the
number of DEGs at 96 h.p.i compared to WT NS1 (Figure 3.6). In a luciferase reporter assay,
IFNβ promoter-driven transcription was inhibited by NS1 Y125A, but less than half as much as
by WT NS1128. Thus, I asked whether the Y125A mutant would impact the capacity of NS1 to
suppress transcription driven by these promoters.

Figure 4.3. Transcription driven by optimized ISRE-5x reporter construct is lower in the presence of
either WT or Y125A NS1. Bar graphs show the fold change of the firefly/nanoLuc ratio for the ISRE-5x
promoter normalized to the minimal promoter/nanoLuc ratio for the same condition. Grey bars,
unstimulated and green bars, stimulated in A, with polyI:C stimulus; B, with IFNβ stimulus; C, with TNFα. EV, pCAGGS empty vector; WT, pCAGGS-3HA-FLAG-NS1 WT; Y125A, pCAGGS-3HA-FLAG-NS1
Y125A. Numbers below bars indicate the level of expression compared to empty vector transfected cells
with the same stimulus. Unpaired t-test, *, p < 0. 05; **, p < 0.005; ***, p < 0.0005. Representative of three
or more independent experiments.
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Having the ISRE-5x construct at my disposal, I tested the effect of WT and Y125A NS1
on ISRE-driven transcription in stimulated 293Ts. A plasmid encoding NS1 WT or Y125A point
mutant (or an empty vector plasmid) was transfected with the ISRE-5x reporter construct and cells
were stimulated with the indicated reagent. To demonstrate the varying impact of different immune
stimulants on different reporter constructs, Figures 4.3 – 4.6 show unstimulated and stimulated
data for each stimulus/reporter combination. As expected, polyI:C stimulation of 293Ts transfected
with the ISRE-5x plus an empty vector construct showed 21-fold increased luciferase activity over
the ISRE-5x in unstimulated cells (Figure 4.3A). For cells transfected with WT NS1, polyI:C
stimulus led to only a six-fold increase in reporter expression, three-fold lower than the change in
stimulated cells transfected with the empty vector. For cells transfected with Y125A NS1 there
was a five- and a half-fold increase in luciferase activity in the polyI:C stimulated condition vs
unstimulated, or similar to the six-fold increase observed for polyI:C stimulated cells transfected
with WT NS1. Notably, even without polyI:C stimulation, the presence of NS1 decreases
luciferase activity driven by the ISRE compared to cells transfected with EV: three-fold lower than
EV for WT NS1 and two fold lower for Y125A NS1.
The same experiment was repeated in interferon-β stimulated cells (Figure 4.3B), and a
similar pattern was observed. A 55-fold increase in ISRE-driven reporter expression was observed
upon IFN-β stimulus in EV-transfected cells, but only a 20-fold increase in the presence of either
WT or Y125A NS1. In the uninduced condition, expression was halved in the presence of either
WT or Y125A NS1. The fifty five-fold increase in luciferase activity of the ISRE-5x induced by
IFNβ stimulus was almost three times that induced by polyI:C. In the presence of WT or Y125A
NS1 luciferase activity decreased almost three-fold compared to IFNβ plus empty vector, which
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was similar to the reduction of expression observed in polyI:C stimulated cells in the presence of
NS1.
Finally, I tested the impact of tumor necrosis factor α (TNF-α) stimulus on ISRE-5x
(Figure 4.3C). TNF-α stimulus led to only a three-fold increase in ISRE-5x driven reporter
expression. This is expected because TNF-α does not strongly activate transcription factors that
bind ISRE-5x. The increase in expression in TNF-α stimulated cells was twenty fold less than that
of IFN-β and eight fold less than that of polyI:C. Expression of WT or Y125A NS1 in TNF-α
stimulated cells reduced luciferase activity about five-fold (WT) or three-fold (Y125A) compared
to TNF-α plus empty vector. Activity in the presence of WT or Y125A NS1 was similar to that
with IFN-β but less reduction than with polyI:C, but for Y125A was less reduction than with
polyI:C or IFN-β.
Next, I asked whether the suppressive effect on transcription observed in the presence of
NS1 was specific to pathways that activate transcription factors specific to the ISRE-5x construct
or whether it was applicable to other transcriptional pathways involved in the innate immune
response. NF-KB is another major pathway of immune response154–157. While the NF-kB pathway
(Figure 1.2) is induced by TLR3 downstream of dsRNA detection, it is not known to be strongly
induced downstream of IFNβ stimulus, but rather is a target of signaling downstream of TNF-
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α68,154,155. Therefore, I decided to test an optimized NF-kB reporter construct (NF-kB-4x) in these
luciferase assays.

The NF-kB-4x luciferase construct is induced with polyI:C two and a half-fold over
unstimulated, which, as expected, is lower (eight-fold) than the ISRE-5x construct (Figure 4.4A).

Figure 4.4. Transcription driven by optimized NF-kB-4x reporter construct is lower in the presence
of either WT or Y125A NS1. Bar graphs show the fold change of the firefly/nanoLuc ratio for the ISRE5x promoter normalized to the minimal promoter/nanoLuc ratio for the same condition. Grey bars,
unstimulated and green bars, stimulated in A, with polyI:C stimulus; B, with IFNβ stimulus; C, with TNFα. EV, pCAGGS empty vector; WT, pCAGGS-3HA-FLAG-NS1 WT; Y125A, pCAGGS-3HA-FLAG-NS1
Y125A. Numbers below bars indicate the level of expression compared to empty vector transfected cells
with the same stimulus. Unpaired t-test, *, p < 0. 05; **, p < 0.005; ***, p < 0.0005. Representative of three
or more independent experiments.

Even without stimulation, luciferase activity was decreased ten-fold in the presence of NS1 WT
and five to ten-fold in the presence of NS1 Y125A. The magnitude of the decrease in reporter
expression driven by the NF-kB-4x in the presence of NS1 (WT or Y125A) was about three-fold
greater than that driven by the ISRE-5x promoter in polyI:C or IFN-β stimulated cells. In TNF-
stimulated cells the difference in magnitude between ISRE-5x and NF-kB RE-4x was even greater,
four- (WT) to twelve-fold (Y125A). PolyI:C-induced NFkB-RE-4x driven reporter expression was
decreased three-fold more in the presence of NS1 than was ISRE-5x driven reporter expression.
Unlike ISRE-5x and as expected, NF-kB-4x driven transcription is not induced by IFNβ treatment
(Figure 4.4B). NF-kB-4x driven reporter expression was reduced around ten-fold in the presence
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of NS1 WT or Y125A for the unstimulated cells, 30-fold in polyI:C stimulated cells, about 20-fold
in IFN-β stimulated cells, and 20- (WT) to 40-fold (Y125A) in TNF- stimulated cells. In contrast,
and as expected, the NF-kB-driven luciferase activity is strongly induced >140-fold in response to
TNF-α stimulus (Figure 4.4C). TNF-α induced NF-kB-driven luciferase expression was reduced
20-fold in the presence of either WT or Y125A NS1. This reduction is four (WT) to eight (Y125A)
times greater than the five-fold decrease in IFNβ stimulated ISRE-5x activity in the presence of
WT NS1.
To summarize, I found that gene expression in the presence of NS1 decreases for three of four
NS1-binding IFIT locus regulatory element reporters. I also found that NS1 represses transcription
induced by polyI:C- and IFN-β-mediated signaling. Indeed, the ISRE-5x construct is repressed in

Figure 4.5. Transcription driven by the IFIT3 promoter is lower in the presence of WT or Y125A
NS1. A, map of the IFIT3 promoter region cloned upstream of the minimal luciferase promoter in pGL4.23.
TSS is at position 1. B – D, Grey bars, unstimulated and green bars, stimulated. Stimuli: B, polyI:C; C,
IFNβ; D, TNF-α. EV, pCAGGS empty vector; WT, pCAGGS-3HA-FLAG-NS1 WT; Y125A, pCAGGS3HA-FLAG-NS1 Y125A. The y axis shows the fold change the firefly/nanoLuc ratio for the ISRE-5x
promoter over that for the minimal promoter in the same condition. Numbers below bars indicate the level
of expression compared to empty vector transfected cells with the same stimulus. Unpaired t-test, *, p <
0.05; **, p < 0.005; ***, p < 0.0005. Representative of three or more independent experiments.
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the presence of WT NS1 in both polyI:C (ten-fold) and IFN-β (five-fold) stimulated cells.
Furthermore, in the presence of Y125A NS1, reporter expression driven by this construct also
decreases in polyI:C (seven-fold) and IFN-β (five-fold) stimulated cells. Finally, in an uninduced
condition, reporter expression is suppressed up to ten-fold in the presence of WT or Y125A NS1.

4.4 In the presence of NS1, IFIT3 promoter drives lower transcription while ISG20 promoter full
length and truncation variants drive similar or higher levels of transcription in a motif-specific
manner
The ISRE-5x and NF-kB-4x reporter constructs used in studies above were optimized for
activation by their respective stimulation pathways. Genomic regulatory elements are multifaceted
and multifunctional, with some having complex networks of transcription factors that enable tight
regulation of transcription. For stress responsive genes such as those involved in the innate immune
response, tight regulation is especially important158–160. Runaway or uninhibited gene expression
carries the risk of adverse reactions. Therefore, I wanted to ask whether, like the optimized
luciferase promoter constructs, NS1-bound regulatory elements would drive reduced transcription
in the presence of NS1.
I first selected the IFIT3 promoter, which encompasses an NS1 binding site (Figure 4.5). IFIT3
is an interferon stimulated gene whose protein product binds and inhibits cellular protein activity
during infection145,146. IFIT3 is upregulated during hRSV infection (Figure 3.6A). The IFIT C
reporter contains the promoter for IFIT3 (Figure 4.2) but was cloned using different primers. This
cloned fragment is a 336 bp fragment overlapping the transcription start site of an IFIT3 isoform.
It contains one NS1 binding sites and two variations of the ISRE motif as well as several GAAA
half-sites.
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I tested the IFIT3 promoter using luciferase assays in cells stimulated with polyI:C, IFNβ, or TNF-α (Figure 4.5). Unlike the ISRE-5x, IFIT3 promoter-driven activity was not consistently
reduced by NS1 when uninduced. Both polyI:C (three-fold) and IFN-β (18-fold) induced luciferase
expression. In the polyI:C induced condition (Figure 4.5B), addition of WT (three-fold) and
Y125A NS1 (two-fold) was associated with decreased expression driven by the IFIT3 promoter.
With IFN-β induction (Figure 4.5C), expression in the presence of WT or Y125A NS1 was
decreased three-fold relative to EV. However, TNF-α (Figure 4.5D) did not alter expression driven
by the IFIT3 promoter, and there was no significant change in expression in the presence of either
WT or Y125A NS1 in TNF-α treated cells. The transcriptional changes observed with these stimuli
agree with their roles in the innate immune response. IFIT3 is an interferon stimulated gene, and
when I searched the full sequence for transcription factor binding sites (Figure 4.4A) there were
no kappa B sites. Thus, upregulation of gene expression under the control of the IFIT3 promoter
is driven by ISRE binding transcription factors, but not by NF-kB family members. IFIT3
promoter-driven luciferase expression decreased in the presence of NS1 WT in polyI:C or IFN-β
stimulated cells. Y125A NS1 also decreased IFIT3-driven luciferase, but less than WT, and the
difference was significant only in the presence of in polyI:C, not IFN-β.
While the ISRE-5x construct was induced 21-fold by polyI:C relative to unstimulated, the
IFIT3 promoter was induced only three-fold. Similarly, IFN-β induced 55-fold higher expression
from the ISRE-5x construct and 18-fold increased expression from the IFIT3 promoter. Expression
decreased by 10-fold in the presence of WT NS1 in polyI:C-stimulated cells under control of the
ISRE-5x, but only three-fold for the IFIT3 promoter. ISRE-5x driven expression decreased sevenfold and IFIT3 promoter driven expression decreased two-fold in the presence of NS1 in polyI:C
stimulated cells.
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For IFN-β stimulated cells, ISRE-5x drove five-fold lower expression in the presence of
WT NS1 or Y125A NS1 than in the presence of empty vector. For the IFIT3 promoter, expression
in IFN- stimulated cells decreased by about three-fold with the addition of WT NS1 or Y125A
NS1.

4.5 Reporter expression driven by the ISG20 promoter is increased in the presence of NS1
Next, I returned to my list of RSV-infection DEGs with NS1 binding sites at nearby regulatory
elements. ISG20 was notable as this gene encodes an endoribonuclease that has activity against
multiple RNA viruses161–164. There is an NS1 binding site just upstream of the transcription start
site for two of three isoforms shown on GENCODE V36.
I tested the ISG20 promoter (Figure 4.6) in a luciferase promoter assay as before. In this case,
in unstimulated cells expression increased 1.5-fold in the presence of WT NS1 but not NS1

Figure 4.6. Transcription driven by the ISG20 promoter reporter is increased in the presence of either
WT or Y125A NS1. A, cartoon of the cloned region of the ISG20 promoter, with transcription factor
binding sites identified by Gongora et al and/or myself indicated. Gene start is at position 1 and proceeds
to 200. Created in SnapGene Viewer. Grey bars, unstimulated and green bars, stimulated in B, with polyI:C
stimulus; C, with IFNβ stimulus; D, with TNF-α. EV, pCAGGS empty vector; WT, pCAGGS-3HA-FLAGNS1 WT; Y125A, pCAGGS-3HA-FLAG-NS1 Y125A. The y axis shows the fold change the
firefly/nanoLuc ratio for the ISRE-5x promoter over that for the minimal promoter in the same condition.
Numbers below bars indicate the level of expression compared to empty vector transfected cells with the
same stimulus. Unpaired t-test, *, p < 0.05; **, p < 0.005; ***, p < 0.0005. Representative of three or more
independent experiments.
48

Y125A. There was no significant change in expression in polyI:C stimulated cells in the presence
of either WT or Y125A NS1. In IFN- stimulated cells, expression again increased 1.5-fold with
the addition of WT NS1 but did not significantly change with the addition of Y125A NS1. In TNF stimulated cells, both WT and Y125A NS1 were associated with a 1.67-fold increase in
luciferase expression vs. empty vector.
To conclude this section, I found that in the presence of NS1, the IFIT3 promoter drives about
three-fold less transcription in polyI:C stimulated cells than without. Similarly, it drives about
three-fold as much transcription in IFN- stimulated cells in the presence of NS1 compared to
without. In unstimulated cells, or those stimulated with polyI:C or IFN-, decreased reporter
expression is also observed. In contrast, the ISG20 promoter transcription is essentially unchanged
with NS1 and polyI:C or IFN but drives higher levels of transcription in the presence of and
TNF-.
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Figure 4.7. Truncated variants of the ISG20 promoter may drive either a decrease or
increase in expression in response to stimulus and in the presence of NS1. A, the ISG20
promoter as shown in Figure 4.6 but with the motifs of interest highlighted: NF-kB RE in blue,
and ISRE in purple. B, a simplified cartoon of the full length ISG20 promoter and truncation
mutants indicating the relative locations of the indicated transcription factor binding sites. CN, luciferase reporter assay was performed as before using the indicated variant of the ISG20
promoter to drive luciferase expression. Bars in grey are unstimulated and bars in green are
stimulated. Unpaired t-test, *, p < 0.05; **, p < 0.005. All graphs are representative of at least
two independent experiments.
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4.6 Truncation variants of the ISG20 promoter respond differently to stimulus and in the presence
of NS1
About two decades ago, the Mechti group165 identified several transcription factor binding
sites (TFBS) throughout the ISG20 promoter: GAS, NF-kB RE, all GC boxes, E.box, GATA, and
ISRE, some of which agree with elements I manually identified: HA-NS1, NF-kB RE, ISRE, and
NF-kB RE 2. Therefore, I decided to break down the ISG20 promoter construct, as originally
cloned, into segments containing either the NF-kB motif (I20 NF-kB RE), the ISRE motif (I20
ISRE), or both (I20 kB/IS), but excluded the GAS identified by the Mechti group and the second
NF-kB RE that I manually identified (Figure 4.7B).
I then tested the full length ISG20 promoter, or I20 FL, along with I20 NF-kB RE; I20 ISRE;
and I20 kB/IS (Figure 4.7C-N). Expression driven by I20 FL in cells stimulated with polyI:C
increased two and a half-fold in the presence of NS1. I20 NF-kB RE was induced by one and a
half fold. I20 ISRE was induced by two-fold but had basal expression of about half that of I20 FL.
I20 kB/IS was also upregulated two-fold by NS1. In the experiment shown, the ISG20 promoter
was not induced by IFN-β or TNF-α.
With IFN-β stimulus, reporter expression decreased under the control of all ISG20 promoter
variants. When NS1 was added to IFN-β stimulated cells, expression increased two-fold for the
ISG20 FL construct and one and a half fold for either the ISG20 NF-kB RE or ISG20 ISRE
construct but remained about the same for the ISG20 kB/IS construct.
With TNF-α stimulus, reporter expression was not upregulated in the experiment shown for
any of the tested ISG20 promoter variants. Neither was there a significant change in expression in
the presence of NS1.
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However, the Mechti group observed an induction of 7.2-fold165 by polyI:C of their longest
ISG20 promoter construct165. This construct is 170 nt longer than my ISG20 FL construct. This
indicates to me that I could use a longer promoter construct to observe higher induction. However,
the Mechti group observed consistent upregulation of ISG20 promoter driven reporter expression
even for truncated variants of the promoter165. Thus, quantity and choice of IFN stimulus could be
further optimized for induction of truncated ISG20 promoter variants. The experiment could be
conducted in different cells to better recapitulate the physiological conditions of induction.

4.7 Discussion
In Chapter 4, I asked whether NS1 acted as a transcriptional modulator of gene expression
driven by genomic regulatory elements at which it binds. I used optimized reporter plasmids to
test the effect of NS1 on promoters regulated by specific TFs. Then I cloned NS1-bound genomic
regulatory elements to test the effect of NS1 on a more physiological DNA sequence. To provide
immune signaling context, I used a dsRNA mimic, IFN-β, or TNF- to activate signaling pathways
that alter transcription downstream of detected pathogens.
Because I found that fewer than half of NS1 sites overlapped Mediator binding sites, yet
nearly all were in transcriptional regulatory elements, I hypothesized that NS1 interacts with other
transcription factors. RIG-I signaling activates the IRF3 and IRF7 transcription factors, members
of the IRF family of transcription factors36,76,82. IRF family transcription factors, which are
involved in the innate immune response, bind the ISRE motif, for which the consensus is
GAAANNGAAA87,149,149,166–168. TLR3 is the other major pattern recognition receptor that
recognizes dsRNA64,93,94,94,95; the NF-kB transcription factor is activated downstream of the TLR3
signaling pathway. The consensus motif for NF-kB is GGGNNTTCCC154,155,169,170.
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I used optimized, commercially available reporter plasmids to test gene expression in the
presence of NS1 under the control of promoters carrying each motif. An optimized reporter
plasmid ISRE-5x, which contains five repeats of the GAAANNGAAA motif, drives increased
reporter expression in response to innate immune stimuli, including polyI:C, IFN-β. It also drives
increased expression TNF- stimulated cells. I showed that ISRE-5x also drives lower gene
expression in the presence of NS1. Another optimized reporter plasmid, NF-kB-4x, which contains
four repeats of GGGNNTTNCC and is stimulated by polyI:C and TNF-α, also drove lower reporter
gene expression in the presence of NS1. However, the NF-kB-4x drove relatively lower expression
upon the addition of NS1 in polyI:C stimulated cells than did the ISRE-5x. For both ISRE-5x and
NF-kB-4x optimized reporter plasmids, expression in unstimulated cells as well as polyI:C and
IFN-β stimulated cells was lower in the presence of either WT or Y125A NS1. ISRE-5x and NFkB-4x mediated reporter expression in the presence of either WT and Y125A NS1 was lower in
TNF-α stimulated cells as well. PolyI:C and IFN-β are both innate immune signals directly
involved in the response to acute viral infection64,73,74,92,171–175, whereas TNF-α is directly relevant
for NF-kB activation and inflammatory signaling154,155. IRF family member transcription factors
are directly activated downstream of polyI:C and IFN-β stimulus176. However, NF-kB family
member transcription factors are directly activated downstream of polyI:C or TNF-α, but not IFNβ, stimulus154,155,173,177.
Genomic regulatory elements, which carry their current sequence and are conserved for
their functionality rather than engineering, are those with which NS1 would interact in the course
of viral infection. Testing NS1 bound regulatory elements within the IFIT locus with the luciferase
reporter assay provided evidence that such regulatory elements drive altered gene expression in
the presence of NS1. The genes regulated by these elements are interferon-stimulated genes
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strongly induced during hRSV infection. As these elements drive lower reporter gene expression
in the presence of NS1, they may similarly drive lower expression of the IFIT genes in hRSV
infected cells. While the RNA-sequencing for NS1 Y125A hRSV infected A549s shows that the
IFIT transcriptome is more like that of mock than of WT NS1 hRSV infection, this is in context
of an infection in which the WT but not Y125A NS1 bearing virus continues to replicate at 96
hpi128.
I next tested the effect of NS1 Y125A on transcription driven by the IFIT3 promoter. I
found that reporter expression driven by the IFIT3 promoter in polyI:C stimulated cells was
markedly less decreased in the presence of Y125A NS1 (about twice as much total expression vs
WT, p < 0.05), whereas gene expression driven by the ISRE-5x promoter in polyI:C stimulated
cells underwent a ten-fold decrease in the presence of both WT and Y125A NS1. While optimized
promoter constructs drive a consistent decrease in reporter expression in the presence of NS1, they
lack the complexity of genomic regulatory elements. This difference may explain why
transcription driven by the optimized promoters was more profoundly reduced in the presence of
NS1 than by the genomic regulatory elements.
Within the genome, variants of consensus motifs bind transcription factors with different
affinities103,166–168, which in turn modulates the level of regulation that any one transcription factor
has on a specific gene. Discrete combinations of transcription factors such as IRF3, IRF7, and NFkB have also been shown to modulate expression of individual genes103,178–180. At a gene such as
IFIT3, the promoter element may bind IRF3 homodimers or IRF3/7 heterodimers activated
downstream of RIG-I signaling. The IFIT3 promoter also has a tripartite ISRE where an IRF3
trimer may bind. While the ISRE-5x promoter contains five consecutive GAAANNGAAA motifs
and measures 75 bp, the IFIT3 promoter contains one bipartite and one tripartite ISRE motif and
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measures 336 bp. Therefore, motifs not shared between the ISRE-5x and the IFIT3 promoters may
account for the demonstrated difference in gene expression in the presence of NS1 WT vs. Y125A.
Changes in gene expression may also be ascribed to the signaling pathway that is activated.
ISRE consensus-like motifs are bound by IRF3/7 downstream of RIG-I signaling, but by ISGF3
downstream of IFN-β signaling71,97. The ISRE-5x is more strongly induced by IFN-β than by
polyI:C, and there is a stronger decrease in gene expression in the presence of NS1 downstream of
polyI:C than downstream of IFN-β. IRF9 and IRF3 only share 26% sequence identity by protein
BLAST181. NS1 is known to interact strongly with IRF3, but it is not known whether it strongly
interacts with other family members such as IRF9.
I next asked whether promoter regions near DEGs outside of the IFIT locus continued the
pattern of lower expression in the presence of NS1. I focused on the ISG20 promoter for this next
set of experiments, as in addition to an ISRE motif, the ISG20 promoter harbors at least one
instance of the NF-kB RE. In contrast to the IFIT3 promoter, in the presence of NS1 the ISG20
promoter drove increased gene expression. I hypothesized that additional regulatory elements
within the ISG20 promoter or a combination not present in the IFIT3 promoter were responsible
for the opposite effect on gene expression. As well as ISRE and NF-kB regulatory elements, the
ISG20 promoter contains several additional regulatory sequences that might explain the distinct
transcriptional response to NS1. These include GAS, E.box, GATA, and GC elements165. Previous
work by the Mechti group indicates that the ISG20 expression may be induced by NF-kB and IRF1
in Daudi cells164. Additionally, GC boxes may bind SP1 family transcription factors. These GC
boxes were discussed in Gongora et al165 as potential motifs driving basal ISG20 transcription.
However, the same paper demonstrated that a truncated promoter lacking the GC box elements but
including the ISRE and a 5’ UTR overlapping region of the promoter still drove increased
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expression vs that of a control vector165. Independent work by the Pentecost group identified ISG20
as an estrogen modulated gene182. Serial truncations indicated that several motifs throughout the
promoter region increase the level of transcription165 from the basal rate. Therefore NF-kB and
IRF family transcription factors alone fail to fully account for ISG20 promoter driven transcription.
The SP-1 transcription factor may also bind the GC box motifs183 and Myc/Max heterodimers may
bind the E. box motif184. SP-1 has both activating and suppressive functions dependent on context.
In some tissues SP-1/NF-kB complexes lead to upregulation of gene expression185,186. Determining
which transcription factors bind throughout the ISG20 promoter downstream of innate immune
signaling will be important to determine which are involved in the upregulation of gene expression
in the presence of NS1.
Alternatively, the presence of both NF-kB RE and ISRE motifs within the same promoter
could affect gene transcription differently than the presence of only one or the other. As the second
NF-kB RE element that I annotated manually is within the 5’ UTR of the ISG20 promoter
fragment, I suggest that it is involved in ISG20 promoter-driven transcription. While both IRF3
and NF-kB may be present within the nucleus, NS1 may disrupt the interaction of IRF3 with
regulatory elements due to its interaction with Mediator and chromatin. Where IRF3 and NF-kB
might bind the same regulatory element in the absence of NS1, then in the presence of NS1 one or
the other may be sterically excluded. This could disrupt the timing and duration of transcriptional
upregulation. Furthermore, if a transcription factor such as SP-1, which can act as either inducer
or repressor in a context dependent manner, were to remain bound to the promoter, then absence
of an innate immune specific transcription factor required for the antiviral action of SP-1 (either
inducing or repressing) might permit SP-1 to act as the opposite: repressing where the antiviral
action would be inducing, or vice versa. Such a mechanism might involve the combined activity
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of SP-1 with NF-kB183,185,186, but the interaction of NS1 with NF-kB might abolish its association
with SP-1.
The non-enzymatic IFIT proteins interact with several binding partners including eIF3187
in complex with which they inhibit translation. IFIT3 specifically enhances the antiproliferative
activity of cell cycle mediators p21 and p27188,189, and enhances RIG-I signaling190, among several
functions144–146. Furthermore, the protein encoded by ISG20 is an endonuclease preferentially
active against single-stranded RNAs162–164 and has known antiviral activity against influenza virus,
a negative sense RNA virus191 like RSV, as well as multiple positive sense RNA viruses192.
Transcription is highly induced during hRSV infection. Taken together, these results indicate that
ISG20 is upregulated during acute viral infection as an antiviral defense measure. However,
sustained expression of ISG20 may increase the amount of cellular RNAs processed by ISG20.
This could increase cell stress and raise the risk of long-term inflammation, a known effect of
hRSV infection.
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Chapter 5: Future directions and concluding remarks
5.1 DNA affinity precipitation assay and electrophoretic mobility shift assay may be used to
confirm association of NS1 with host transcription factors at genomic TF binding motifs
A biochemical assay can be used to demonstrate an association of NS1 with host
transcription factors on chromatin. Two methods commonly used in the literature are the DNA
affinity precipitation assay (DAPA), previously utilized by our group to identify cancer associated
single nucleotide polymorphisms that alter transcription factor binding affinity193, and the
electrophoretic mobility shift assay (EMSA)194.
In the DAPA assay, I transfected 293Ts with an HA-tagged IRF3-5D expressing plasmid,
then incubated with oligonucleotides containing an interferon stimulated regulatory element
(ISRE) or scrambled oligo (Figure 5.1). By overexpressing IRF3 and/or NS1 and incubating with
oligonucleotides encoding the ISRE monomer or a scrambled sequence, this assay can be used to
test whether addition of NS1 reduces the binding capacity of IRF3 to the ISRE.
While the IRF3-5D construct was used in the experiments illustrated below, IRF3 is not
the only transcription factor that should be considered. The well characterized phosphomimetic,
IRF3-5D36,37,86,87 can be used in experiments requiring activated IRF3 without viral infection or
the addition of stimulus. However, multiple phosphomimetic forms of IRF3 are available including
6D, which has an additional aspartic acid change166. In Daudi cells, the IRF1 transcription factor
has been shown to associate via EMSA with the ISRE motif within the ISG20 promoter165, and so
this combination of transcription factor and oligonucleotide should also be tested in A549s with
NS1. As NS1 has been shown to suppress or otherwise alter reporter transcription downstream of
IFN-βstimulus, IRF9, the IRF component of the ISGF3 complex, is an additional viable candidate.
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NF-kB and SP-1 should also be tested as they are candidates for interaction with NS1 as discussed
in Chapter 4.

Figure 5.1. ISRE motif oligonucleotides bind IRF3-5D. IRF3 WT, IRF3-D, and NS1 were all 3HA
tagged. A, B, (Luciferase) 293Ts were stimulated with polyI:C or IFNB (A), incubated for 24 hours with
a firefly luciferase reporter plasmid with either a minimal promoter, ISRE promoter, or NF-kB (B)
regulatory element promoter and either empty vector (EV) or an NS1 expressing plasmid. The firefly
luciferase (fLuc) ratio over nano luciferase (nLuc, transfection control) was calculated for both EV and
NS1 conditions and normalized to EV for that promoter. C, (DAPA) Cell lysate transfected with plasmid
expressing HA-tagged IRF3 WT (left) or IRF3-5D (right) was incubated with biotinylated
oligonucleotides (sequences shown panel G) and detected with anti-HA antibody. D, (DAPA) Cell lysate
transfected with IRF3-5D + either empty vector or an NS1 expressing plasmid was incubated and detected
as above. E, (EMSA) Control DNA and oligonucleotides included with the LightShift Chemiluminescent
EMSA kit were subjected to EMSA according to the manufacturer’s directions. F, (Cell fractionation)
Cells transfected with IRF3-5D and either empty vector or NS1, with or without polyI:C stimulus, were
fractionated according to the Thermo Scientific Subcellular Protein Fractionation Kit for Cultured Cells.
G, (Oligonucleotide sequences) Forward oligonucleotide sequences used in DAPA and EMSA
experiments. Portion unique to the scrambled oligo is shown in grey and the corresponding portion unique
to the IRF3-IRF5 binding sequence is shown in green. F, (EMSA) Cell lysate transfected with IRF3 +
either empty vector or NS1 was subjected to EMSA with the oligonucleotides shown in panel G. Figure
adapted from June 2021 thesis progress report.
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5.2 NS1 a3 helix variants and other hRSV proteins should be subjected to chromatin profiling
Several residues within the α3 helix of NS1 may modulate of the transcriptional regulatory
effect of the protein. NS1 variants should be immunoprecipitated with chromatin through
chromatin immunoprecipitation, or else by a similar technique such as CUT&RUN195. CUT&RUN
offers advantages over ChIP in that there is lower inherent background and that lower cell counts
may yield sufficient DNA for identification of peaks.
5.3 Studies may be expanded to additional cell types
hRSV is a respiratory virus, thus physiologically relevant tissues throughout the airway
should be tested for NS1 chromatin occupancy. Primary human tracheobronchial epithelial cells
(hTECs) can be infected with hRSV. With the novel anti-NS1 antibody as a tool, infected hTECs
could be subjected to CUT&RUN-sequencing to profile chromatin bound NS1.
Concluding remarks
The studies detailed here demonstrate a novel, chromatin associated role for NS1, an
interferon antagonist protein previously shown to act only in the cytoplasm. First, I demonstrated
that NS1 associates with several hundred regulatory elements throughout the genome.
Furthermore, I showed these regulatory elements are enriched at genes that are differentially
expressed during hRSV infection and involved in the innate immune response. At least a subset of
these regulatory elements drive altered reporter gene expression in the presence of NS1. This
transcriptional regulatory role of NS1 provides a more complete picture of the extent to which
hRSV disrupts of host immune response. Together, these studies provide an exciting new avenue
through which to explore the biological basis for severe or recurring hRSV infection.
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